Back to top

Image: Bigstock

Solventum (SOLV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Read MoreHide Full Article

Solventum (SOLV - Free Report) reported $2.16 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 3.8%. EPS of $1.69 for the same period compares to $1.56 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $2.12 billion, representing a surprise of +1.87%. The company delivered an EPS surprise of +16.55%, with the consensus EPS estimate being $1.45.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Solventum performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
  • Net Sales- MedSurg: $1.22 billion compared to the $1.18 billion average estimate based on four analysts. The reported number represents a change of +4.8% year over year.
  • Net Sales- Purification and Filtration: $252 million versus $242.52 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +5.9% change.
  • Net Sales- Health Information Systems: $339 million versus $334.42 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +3.4% change.
  • Net Sales- Dental Solutions: $338 million versus $332.9 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +2.1% change.
  • Operating Income- MedSurg: $210 million versus $215.41 million estimated by two analysts on average.
  • Operating Income- Purification and Filtration: $48 million versus the two-analyst average estimate of $20.15 million.
  • Operating Income- Health Information Systems: $120 million versus the two-analyst average estimate of $112.01 million.
  • Operating Income- Dental Solutions: $96 million versus $89.41 million estimated by two analysts on average.

View all Key Company Metrics for Solventum here>>>

Shares of Solventum have returned -2.2% over the past month versus the Zacks S&P 500 composite's +1.2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Solventum Corporation (SOLV) - free report >>

Published in